drugset / Trial / NCT06012708
Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713
Non-randomizedSequentialOpen-labelTreatment
Summary
To evaluate the safety and tolerability of the combination therapy of KN510 and KN713 and determine the MTD and RP2D in patients with advanced solid tumors.
Timeline
- Start
- 2023-09-11
- Primary completion
- 2024-11-05
- Completion
- 2024-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KN510 | Unknown | 60 mg | — |
| Subject | KN510 | Unknown | 120 mg | — |
| Subject | KN713 | Unknown | 60 mg | — |
| Subject | KN713 | Unknown | 90 mg | — |
| Subject | KN713 | Unknown | 120 mg | — |